The impact of polygenic risk for alzheimer’s disease on neurotransmitter-related grey matter atrophy in the alzheimer continuum
Authors:
Open Access
- 25 August 2025
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (11) , 1-13
Abstract
Alzheimer’s disease (AD) pathology has been recently shown to accumulate in multiple brainstem nuclei in pre-cortical disease stages. However, the impact of neurotransmission alterations on brain atrophy and their genetic correlates in AD remain unexplored. This study investigated (1) associations between grey matter (GM) loss and uptake values of PET/SPECT ligands tracing concentration of multiple neurotransmitter receptors/transporters and pathways; (2) the impact of AD polygenic risk scores (AD-PRSs) on such associations along the AD continuum. T1-weighted MRI scans, genetic and clinical data were selected for 800 ADNI participants: 203 cognitively unimpaired older adults (CU), 442 with mild cognitive impairment (MCI) and 155 with AD. JuSpace was used to calculate correlations between GM volume (GMV) and the concentration of several neurotransmitters. Two PRSs, with (AD-PRS) and without APOE (AD-PRSnoAPOE), were investigated as predictors of the strength of correlation between GMV and neurotransmitters in general linear models. In both patient groups, atrophy was negatively associated with serotoninergic and dopaminergic receptors/transporters. In the whole sample, both PRSs were associated with the strength of correlation between GMV and different serotonin receptors and fluorodopa uptake. The pattern of associations was replicated in participants with evidence of amyloid pathology. GM loss in AD may be particularly affected by the alterations in serotoninergic and in presynaptic dopaminergic activity that are known to influence functioning of medio-temporal and frontal cortices. Such alterations appear to be driven by higher AD-PRS values. Investigating further neurotransmitter-related neural alterations may help clarifying neuropathological changes in pre-clinical AD and response to treatments.Keywords
Funding Information
- Ministero dell'Università e della Ricerca (PE0000006)
This publication has 49 references indexed in Scilit:
- Unravelling neurotransmitters impairment in primary progressive aphasiasHuman Brain Mapping, 2023
- The neural signatures of psychoses in Alzheimer’s disease: a neuroimaging genetics approachEuropean Archives of Psychiatry and Clinical Neuroscience, 2022
- JuSpace: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter mapsHuman Brain Mapping, 2020
- Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease in a Chinese CohortNeuroscience Bulletin, 2020
- Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrumCortex, 2017
- Model-free Estimation of Recent Genetic RelatednessThe American Journal of Human Genetics, 2016
- Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plansAlzheimer's & Dementia, 2015
- Robust Inference of Population Structure for Ancestry Prediction and Correction of Stratification in the Presence of RelatednessGenetic Epidemiology, 2015
- Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current StatusDrugs, 2014
- The Alzheimer's disease neuroimaging initiative (ADNI): MRI methodsJournal of Magnetic Resonance Imaging, 2008